NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $2.80 +0.06 (+2.19%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.68▼$2.8050-Day Range$2.36▼$3.3952-Week Range$1.81▼$3.85Volume5,849 shsAverage Volume24,912 shsMarket Capitalization$69.80 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get InspireMD alerts: Email Address InspireMD MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside60.7% Upside$4.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector659th out of 910 stocksSurgical & Medical Instruments Industry77th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days.Read more about InspireMD's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NSPR. Previous Next 0.0 Dividend Strength Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NSPR. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for InspireMD this week, compared to 0 articles on an average week.Search Interest1 people have searched for NSPR on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.82) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about InspireMD's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About InspireMD Stock (NYSE:NSPR)InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More NSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NSPR Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.comAugust 28, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.comSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Research Coverage Started at StockNews.comAugust 10, 2024 | seekingalpha.comInspireMD, Inc. (NSPR) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | msn.comNexstar Media GAAP EPS of $3.54 misses by $0.11, revenue of $1.27B misses by $10MAugust 7, 2024 | finanznachrichten.deInspireMD, Inc.: InspireMD Congratulates CREST-2 Investigators on Completion of Trial EnrollmentAugust 7, 2024 | markets.businessinsider.comR1 RCM Reports Second Quarter 2024 ResultsSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 7, 2024 | finance.yahoo.comCompanies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In GrowthAugust 6, 2024 | finanznachrichten.deInspireMD, Inc.: InspireMD Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 6, 2024 | finance.yahoo.comInspireMD Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 6, 2024 | globenewswire.comInspireMD Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 5, 2024 | globenewswire.comInspireMD Congratulates CREST-2 Investigators on Completion of Trial EnrollmentJuly 30, 2024 | globenewswire.comInspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6thMay 28, 2024 | globenewswire.comInspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024May 15, 2024 | markets.businessinsider.comInspireMD earnings preview: what Wall Street is expectingMay 14, 2024 | investorplace.comNSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024See More Headlines Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NSPR CUSIPN/A CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$4.50 Low Stock Price Target$4.50 Potential Upside/Downside+60.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-388.67% Pretax Margin-387.68% Return on Equity-62.02% Return on Assets-52.26% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.13 Sales & Book Value Annual Sales$6.57 million Price / Sales10.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book1.49Miscellaneous Outstanding Shares24,930,000Free Float17,521,000Market Cap$69.80 million OptionableOptionable Beta0.90 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Marvin L. Slosman (Age 60)President, CEO & Director Comp: $843.83kMr. Craig Shore (Age 63)CFO, Chief Administrative Officer, Secretary & Treasurer Comp: $613.49kMr. Shane Thomas Gleason (Age 49)Chief Commercial Officer Comp: $486.04kMr. Andrea Tommasoli (Age 52)Chief Operating Officer Comp: $359.27kMr. Amir KohenVice President of Finance & Human ResourcesDr. Patrick A. Verta DVM (Age 66)M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs Mr. Pete LigottiExecutive VP & GM of North AmericaDr. Sol J. Barer Ph.D. (Age 77)Special Advisor to the Board Comp: $13.92kMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHZynexNASDAQ:ZYXIAVITA MedicalNASDAQ:RCELNeuroPaceNASDAQ:NPCEProfound MedicalNASDAQ:PROFView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 39,856 shares on 8/20/2024Ownership: 8.129%Rosalind Advisors Inc.Bought 1,827,579 shares on 7/12/2024Ownership: 10.083%Gary S RoubinBought 50,000 shares on 11/30/2023Total: $126,500.00 ($2.53/share)View All Insider TransactionsView All Institutional Transactions NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $2.81 at the beginning of 2024. Since then, NSPR stock has decreased by 0.4% and is now trading at $2.80. View the best growth stocks for 2024 here. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. The firm earned $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 62.02% and a negative net margin of 388.67%. When did InspireMD's stock split? InspireMD's stock split on Saturday, January 1st 2000. The 15-1 split was announced on Saturday, January 1st 2000. The newly minted shares were issued to shareholders after the closing bell on Tuesday, April 27th 2021. An investor that had 100 shares of stock prior to the split would have 1,500 shares after the split. Who are InspireMD's major shareholders? InspireMD's top institutional shareholders include Rosalind Advisors Inc. (10.08%) and Nantahala Capital Management LLC (8.13%). Insiders that own company stock include Gary S Roubin and Paul Stuka. View institutional ownership trends. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST) and AcelRx Pharmaceuticals (ACRX). This page (NYSE:NSPR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
